Figure 3.

Estimated treatment‐free survival according to patients’ characteristics. The estimated treatment‐free survival rates according to patient characteristics, including sex (A), Sokal score (B), BCR‐ABL1 mRNA‐negative duration (C), duration of tyrosine kinase inhibitor (TKI) treatment (D), age at discontinuation (E), total dose of dasatinib (F), and the type of TKI when achieving a deep molecular response (G) are presented along the y‐axis. In all figures, the duration (months) of discontinuation is shown along the x‐axis. The cut‐off levels of each type of clinical data were determined using receiver operating characteristic (ROC) curve analyses as described in the Methods